Michael A Drebot1, Harvey Artsob. 1. National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Man. mike_drebot@phac-aspc.gc.ca
Abstract
OBJECTIVE: To review the epidemiology and disease manifestations of West Nile virus (WNV) in North America and to describe the current status of therapeutic approaches and vaccines for treating or preventing viral illness. QUALITY OF EVIDENCE: Since 1999, research initiatives investigating the ecology, epidemiology, and biology of WNV have increased substantially. These studies provide a foundation for understanding current activity and predicting future activity and for describing the effect of WNV on human health. MAIN MESSAGE: West Nile virus is transmitted to humans primarily through bites from infected mosquitoes. Most people infected have no symptoms; a few have clinical manifestations ranging from febrile illness to neurologic syndromes and possibly death. Risk of serious disease increases with age, and substantial long-term morbidity has been observed in patients who develop severe neurologic illness. No specific antiviral therapy or vaccine currently exists. CONCLUSION: West Nile virus has established itself in North America and has become an important public health concern. Decreasing risk of virus-associated illness requires seasonal preventive and control measures.
OBJECTIVE: To review the epidemiology and disease manifestations of West Nile virus (WNV) in North America and to describe the current status of therapeutic approaches and vaccines for treating or preventing viral illness. QUALITY OF EVIDENCE: Since 1999, research initiatives investigating the ecology, epidemiology, and biology of WNV have increased substantially. These studies provide a foundation for understanding current activity and predicting future activity and for describing the effect of WNV on human health. MAIN MESSAGE: West Nile virus is transmitted to humans primarily through bites from infected mosquitoes. Most people infected have no symptoms; a few have clinical manifestations ranging from febrile illness to neurologic syndromes and possibly death. Risk of serious disease increases with age, and substantial long-term morbidity has been observed in patients who develop severe neurologic illness. No specific antiviral therapy or vaccine currently exists. CONCLUSION:West Nile virus has established itself in North America and has become an important public health concern. Decreasing risk of virus-associated illness requires seasonal preventive and control measures.
Authors: Bruno P Granwehr; Kristy M Lillibridge; Stephen Higgs; Peter W Mason; Judith F Aronson; Gerald A Campbell; Alan D T Barrett Journal: Lancet Infect Dis Date: 2004-09 Impact factor: 25.071
Authors: Robert B Tesh; Amelia P A Travassos da Rosa; Hilda Guzman; Tais P Araujo; Shu-Yuan Xiao Journal: Emerg Infect Dis Date: 2002-03 Impact factor: 6.883
Authors: Daniel R O'Leary; Anthony A Marfin; Susan P Montgomery; Aaron M Kipp; Jennifer A Lehman; Brad J Biggerstaff; Veronica L Elko; Peggy D Collins; John E Jones; Grant L Campbell Journal: Vector Borne Zoonotic Dis Date: 2004 Impact factor: 2.133
Authors: Nicholas Komar; Stanley Langevin; Steven Hinten; Nicole Nemeth; Eric Edwards; Danielle Hettler; Brent Davis; Richard Bowen; Michel Bunning Journal: Emerg Infect Dis Date: 2003-03 Impact factor: 6.883